Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance

NCT00219791 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: glucarpidase (50 Units/kg)

Sponsor

BTG International Inc.